Intensive Care Unit, University Hospital Taher Sfar, Mahdia, Tunisia.
Research Laboratory, University of Monastir, Mahdia, Tunisia.
Shock. 2019 Nov;52(5):481-486. doi: 10.1097/SHK.0000000000001316.
The best modality of administration of hydrocortisone during septic shock has been poorly evaluated and the guidelines remain unclear in this respect. This study aimed to compare bolus of hydrocortisone to a continuous infusion during septic shock.
Randomized controlled, open-label trial.
Medical ICU of a university hospital.
Adult patients with septic shock requiring more than 2 mg/h (approximately 33.3 μg/mn) of norepinephrine after adequate fluid administration were eligible.Patients already receiving corticosteroids or who have a contraindication to corticosteroids, patients who died within 24 h and those with a decision of not to resuscitate were excluded.
Patients were randomized either to receive hydrocortisone 200 mg/d by continuous infusion or by boluses of 50 mg every 6 h throughout the prescription of vasopressors with a maximum of 7 days.
Twenty-nine patients were included in each group. Shock reversal was significantly higher in the HC bolus group (66% vs. 35%, P = 0.008). The median time to shock reversal was 5 days (95% CI, 4.31-5.69) in the HC bolus group compared to 6 days (95% CI, 4.80-7.19) in the HC continuous infusion group (log Rank = 0.048). The number of hours spent with blood glucose ≥ 180 mg/dL was higher in the HC continuous infusion group with a median of 64 h [IQR (2-100)] versus 48 h [IQR (14-107)] in the HC bolus group, (P = 0.60), and daily insulin requirements were similar between the two groups (P = 0.63). The occurrence of other side effects, mortality, and ICU LOS were similar between the study groups.
Hydrocortisone administered by intermittent bolus was associated with higher shock reversal at day 7 compared with a continuous infusion.
氢化可的松在脓毒性休克中的最佳给药方式评价不佳,指南在此方面尚不明确。本研究旨在比较脓毒性休克时给予氢化可的松推注与持续输注的效果。
随机对照、开放标签试验。
一所大学医院的内科重症监护病房。
需要给予超过 2mg/h(约 33.3μg/min)去甲肾上腺素的脓毒性休克成人患者,且充分液体复苏后仍存在休克。排除正在接受皮质激素或皮质激素禁忌、24 小时内死亡以及无复苏意愿的患者。
患者随机接受氢化可的松 200mg/d 持续输注或每 6 小时给予 50mg 推注,持续使用血管加压药,最多 7 天。
每组纳入 29 例患者。氢化可的松推注组休克逆转率显著更高(66% vs. 35%,P = 0.008)。氢化可的松推注组休克逆转中位时间为 5 天(95%CI,4.31-5.69),而氢化可的松持续输注组为 6 天(95%CI,4.80-7.19)(对数秩检验 P = 0.048)。氢化可的松持续输注组血糖≥180mg/dL 的时间中位数为 64 小时[IQR(2-100)],而氢化可的松推注组为 48 小时[IQR(14-107)],两组间差异有统计学意义(P = 0.60),且两组间胰岛素日需求量相似(P = 0.63)。两组间其他不良反应、死亡率和 ICU 住院时间无显著差异。
与持续输注相比,氢化可的松间断推注可使第 7 天休克逆转率更高。